GlassScriptPhysician profile
Twinkle D Patel
NPI 1205445293
$9,231.99
in general payments reported to CMS, 2019-2025
41 companies · $3,106 in 2025
The $3,106 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,037 · 2024: $3,089 · 2025: $3,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,762 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,762.03 |
| Education | $469.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,813.06 | 2023-2025 | Lynparza, Imfinzi, Calquence |
| Myriad Genetic Laboratories, INC. | $790.28 | 2023-2025 | Myrisk |
| Incyte Corporation | $462.53 | 2023-2025 | Jakafi, Monjuvi |
| Genzyme Corporation | $418.01 | 2023-2025 | |
| Adc Therapeutics America, INC. | $381.52 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $377.91 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $329.94 | 2024-2025 | Datroway, Enhertu |
| Jazz Pharmaceuticals INC. | $329.56 | 2023-2025 | |
| Janssen Biotech, INC. | $327.33 | 2023-2025 | Erleada, Akeega, Balversa |
| Novartis Pharmaceuticals Corporation | $311.77 | 2023-2025 | |
| Tempus Ai, INC | $310.15 | 2024-2025 | Xt Cdx |
| Pfizer INC. | $305.46 | 2023-2025 | |
| Syndax Pharmaceuticals, INC. | $276.56 | 2025 | Revuforj |
| Exelixis INC. | $241.78 | 2023-2025 | Cabometyx |
| Lilly USA, LLC | $236.40 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $234.26 | 2023-2024 | Reblozyl, Opdivo |
| Takeda Pharmaceuticals U.S.A., INC. | $223.64 | 2023-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Genentech USA, INC. | $182.95 | 2023-2025 | Perjeta, Phesgo, Kadcyla |
| Abbvie INC. | $181.09 | 2024-2025 | |
| Immunogen, INC. | $169.25 | 2023 | Elahere |
| Servier Pharmaceuticals LLC | $148.61 | 2023-2025 | |
| Celgene Corporation | $147.24 | 2024-2025 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $140.79 | 2023 | Tukysa |
| Melinta Therapeutics, LLC | $128.47 | 2023 | Kimyrsa, Vabomere |
| Array Biopharma INC | $126.02 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Amgen INC. | $93.63 | 2023-2024 | Prolia, Evenity, Lumakras |
| Puma Biotechnology, INC. | $75.26 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $59.24 | 2024-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $52.48 | 2025 | |
| Pharmaessentia USA Corporation | $49.63 | 2025 | Besremi |
| Deciphera Pharmaceuticals INC. | $46.11 | 2024-2025 | Qinlock, Romvimza |
| Azurity Pharmaceuticals, INC. | $37.32 | 2025 | Vivimusta, Danziten |
| Sobi, INC | $34.62 | 2024 | |
| Mirati Therapeutics, INC. | $32.80 | 2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $30.73 | 2024 | Libtayo |
| Foundation Medicine, INC. | $28.33 | 2023 | |
| Astellas Pharma US INC | $27.45 | 2025 | Xtandi |
| Adaptive Biotechnologies Corporation | $21.99 | 2025 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $20.36 | 2025 | Bylvay |
| Geron Corporation | $18.88 | 2025 | Rytelo |
| Pharmaand Gmbh | $8.58 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Twinkle Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.